Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide in Chinese patients with non-metastatic castration-resistant prostate cancer
CTR20192078Phase 4Completed
- Sponsor
- Janssen Biotech
- Start
- Feb 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of apalutamide in castration-resistant prostate cancer (CRPC), sponsored by Janssen Biotech. Started Feb 2020; status: completed.
02
Drugs
apalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on CTR20192078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192078.